JP7623785B2 - ヒトＡＰＯＥ４およびマウスＴｒｅｍ２ ｐ．Ｒ４７Ｈを発現する遺伝子改変されたマウス、ならびにその使用の方法 - Google Patents

ヒトＡＰＯＥ４およびマウスＴｒｅｍ２ ｐ．Ｒ４７Ｈを発現する遺伝子改変されたマウス、ならびにその使用の方法 Download PDF

Info

Publication number
JP7623785B2
JP7623785B2 JP2019552004A JP2019552004A JP7623785B2 JP 7623785 B2 JP7623785 B2 JP 7623785B2 JP 2019552004 A JP2019552004 A JP 2019552004A JP 2019552004 A JP2019552004 A JP 2019552004A JP 7623785 B2 JP7623785 B2 JP 7623785B2
Authority
JP
Japan
Prior art keywords
mouse
trem2p
apoe4p
disease
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019552004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515248A5 (enExample
JP2020515248A (ja
Inventor
ガレス ハウエル，
マイケル サスナー，
グレゴリー カーター，
ブルース ラム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jackson Laboratory
Original Assignee
Jackson Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson Laboratory filed Critical Jackson Laboratory
Publication of JP2020515248A publication Critical patent/JP2020515248A/ja
Publication of JP2020515248A5 publication Critical patent/JP2020515248A5/ja
Priority to JP2023023328A priority Critical patent/JP2023056032A/ja
Application granted granted Critical
Publication of JP7623785B2 publication Critical patent/JP7623785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019552004A 2017-03-21 2018-03-21 ヒトＡＰＯＥ４およびマウスＴｒｅｍ２ ｐ．Ｒ４７Ｈを発現する遺伝子改変されたマウス、ならびにその使用の方法 Active JP7623785B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023023328A JP2023056032A (ja) 2017-03-21 2023-02-17 ヒトＡＰＯＥ４およびマウスＴｒｅｍ２ ｐ．Ｒ４７Ｈを発現する遺伝子改変されたマウス、ならびにその使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762474358P 2017-03-21 2017-03-21
US62/474,358 2017-03-21
PCT/US2018/023565 WO2018175581A1 (en) 2017-03-21 2018-03-21 A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023023328A Division JP2023056032A (ja) 2017-03-21 2023-02-17 ヒトＡＰＯＥ４およびマウスＴｒｅｍ２ ｐ．Ｒ４７Ｈを発現する遺伝子改変されたマウス、ならびにその使用の方法

Publications (3)

Publication Number Publication Date
JP2020515248A JP2020515248A (ja) 2020-05-28
JP2020515248A5 JP2020515248A5 (enExample) 2021-04-22
JP7623785B2 true JP7623785B2 (ja) 2025-01-29

Family

ID=63586166

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019552004A Active JP7623785B2 (ja) 2017-03-21 2018-03-21 ヒトＡＰＯＥ４およびマウスＴｒｅｍ２ ｐ．Ｒ４７Ｈを発現する遺伝子改変されたマウス、ならびにその使用の方法
JP2023023328A Ceased JP2023056032A (ja) 2017-03-21 2023-02-17 ヒトＡＰＯＥ４およびマウスＴｒｅｍ２ ｐ．Ｒ４７Ｈを発現する遺伝子改変されたマウス、ならびにその使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023023328A Ceased JP2023056032A (ja) 2017-03-21 2023-02-17 ヒトＡＰＯＥ４およびマウスＴｒｅｍ２ ｐ．Ｒ４７Ｈを発現する遺伝子改変されたマウス、ならびにその使用の方法

Country Status (7)

Country Link
US (2) US11957115B2 (enExample)
EP (1) EP3599842B1 (enExample)
JP (2) JP7623785B2 (enExample)
CN (1) CN110891417B (enExample)
AU (1) AU2018239433B2 (enExample)
CA (1) CA3057289A1 (enExample)
WO (1) WO2018175581A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019246483A1 (en) * 2018-06-21 2019-12-26 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
WO2023015153A2 (en) * 2021-08-02 2023-02-09 President And Fellows Of Harvard College ANTISENSE OLIGONUCLEOTIDE TARGETING APOE ε4 AND USES THEREOF
CN114731987B (zh) * 2022-05-19 2023-06-23 华芯微鱼(苏州)生物科技有限公司 颅缝早闭症小鼠模型、其构建方法及应用
CN115536734B (zh) * 2022-11-24 2024-04-30 安徽农业大学 具有肝癌细胞毒性和α-葡萄糖苷酶抑制活性的环色-丙-缬-亮-亮肽及制备方法
CN116103292B (zh) * 2022-11-25 2024-01-30 首都医科大学宣武医院 Zdhhc21基因突变动物模型的构建方法及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001017028A (ja) 1999-05-06 2001-01-23 Mitsubishi Chemicals Corp アポｅヒト化哺乳動物
JP2001057885A (ja) 1999-06-04 2001-03-06 Glaxo Group Ltd スクリーニング
JP2002507898A (ja) 1998-04-30 2002-03-12 ザ ジェイ．デビッド グラッドストーン インスティテューツ アポリポ蛋白質ｅトランスジェニック動物および解析方法
JP2008000027A (ja) 2006-06-20 2008-01-10 Institute Of Physical & Chemical Research アルツハイマー病モデル動物およびその用途
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
EP1772516A1 (en) 1994-10-18 2007-04-11 Dendreon Corporation Pharmaceutical compositions for the treatment of thrombosis
CN1206421A (zh) 1995-11-01 1999-01-27 科斯药品公司 载脂蛋白e2和阿尔采默氏病的治疗
US6175057B1 (en) * 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2001007627A1 (en) 1999-07-21 2001-02-01 Albert Einstein College Of Medicine Of Yeshiva University Drosophila recombination-associated protein and methods for use
US6830910B1 (en) 1999-07-21 2004-12-14 Albert Einstein College Of Medicine Of Yeshiva University Drosophila recombination-associated protein and methods for use
JP4414332B2 (ja) * 2002-07-12 2010-02-10 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマーｔａｕタンパク質を発現するトランスジェニック動物
ES2327914T3 (es) 2002-08-07 2009-11-05 Novartis Ag Metodo para pronosticar la sensibilidad al tratamiento con ravastigmina basado en el genotipo apoe de pacintes con demencia.
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US20060272038A1 (en) 2005-05-27 2006-11-30 Michael De Vivo Transgenic Alzheimer's mouse model vectors and uses thereof
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
EP2213731B1 (en) 2006-05-25 2013-12-04 Sangamo BioSciences, Inc. Variant foki cleavage half-domains
EP2303304A4 (en) 2008-07-01 2011-09-21 Cognosci Inc METHOD FOR THE TREATMENT OF CANCER WITH APOE PEPTIDES
NZ710443A (en) * 2008-08-12 2019-03-29 Zinfandel Pharmaceuticals Inc Method of identifying disease risk factors
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
CA2783351C (en) 2009-12-10 2021-09-07 Regents Of The University Of Minnesota Tal effector-mediated dna modification
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US20150337030A1 (en) * 2012-05-31 2015-11-26 The Trustees Of Columbia University In The City Of New York Methods to treat alzheimer's disease using apoe inhibitors
JP2019531332A (ja) * 2016-07-22 2019-10-31 ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） Ｔｒｅｍ２切断モジュレーター及びその使用
WO2019246483A1 (en) 2018-06-21 2019-12-26 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
US20220099659A1 (en) 2019-01-23 2022-03-31 The Regents Of The University Of California Human Genomic Construct Reporter Cells and Mouse Models to Screen Therapeutics against Microglia-expressed Disease Associated Genes
JP2024500103A (ja) 2020-12-16 2024-01-04 ザ ジャクソン ラボラトリー ヒトａｐｐまたはヒト化ａｐｐと変異型ヒトｐｓｅｎ１とを発現する遺伝子改変免疫不全マウス

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002507898A (ja) 1998-04-30 2002-03-12 ザ ジェイ．デビッド グラッドストーン インスティテューツ アポリポ蛋白質ｅトランスジェニック動物および解析方法
JP2001017028A (ja) 1999-05-06 2001-01-23 Mitsubishi Chemicals Corp アポｅヒト化哺乳動物
JP2001057885A (ja) 1999-06-04 2001-03-06 Glaxo Group Ltd スクリーニング
JP2008000027A (ja) 2006-06-20 2008-01-10 Institute Of Physical & Chemical Research アルツハイマー病モデル動物およびその用途
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ｂｕｉｌｄｉｎｇ Ｂｅｔｔｅｒ Ｍｏｕｓｅ Ｍｏｄｅｌｓ ｆｏｒ Ｌａｔｅ－Ｏｎｓｅｔ Ａｌｚｈｅｉｍｅｒ’ｓ，ＡＬＺＦＯＲＵＭ，２０１７年０１月２０日，ｐ．１－８，ＵＲＬ：ｈｔｔｐｓ：／／ｗｗｗ．ａｌｚｆｏｒｕｍ．ｏｒｇ／ｎｅｗｓ／ｒｅｓｅａｒｃｈ－ｎｅｗｓ／ｂｕｉｌｄｉｎｇ－ｂｅｔｔｅｒ－ｍｏｕｓｅ－ｍｏｄｅｌｓ－ｌａｔｅ－ｏｎｓｅｔ－ａｌｚｈｅｉｍｅｒｓ
Ｏｌｅｎａ Ｋｏｒｖａｔｓｋａ ｅｔ ａｌ．，ＪＡＭＡ Ｎｅｕｒｏｌｏｇｙ，２０１５年０８月，Ｖｏｌ．７２，Ｎｏ．８，ｐ．９２０－９２７
Ｕｎｂｉａｓｅｄ Ｓｃｒｅｅｎ Ｆｉｎｇｅｒｓ ＴＲＥＭ２ Ｌｉｇａｎｄｓ Ｔｈａｔ Ｐｒｏｍｏｔｅ Ａβ Ｕｐｔａｋｅ，ＡＬＺＦＯＲＵＭ，２０１６年０７月２２日，ｐ．１－５，ＵＲＬ：ｈｔｔｐｓ：／／ｗｗｗ．ａｌｚｆｏｒｕｍ．ｏｒｇ／ｎｅｗｓ／ｃｏｎｆｅｒｅｎｃｅ－ｃｏｖｅｒａｇｅ／ｕｎｂｉａｓｅｄ－ｓｃｒｅｅｎ－ｆｉｎｇｅｒｓ－ｔｒｅｍ２－ｌｉｇａｎｄｓ－ｐｒｏｍｏｔｅ－ａｖ－ｕｐｔａｋｅ
Ｙｕ－Ｗｅｎ Ａｌｖｉｎ Ｈｕａｎｇ ｅｔ ａｌ．，Ｃｅｌｌ，２０１７年０１月２６日，Ｖｏｌ．１６８，ｐ．４２７－４４１
野島 博，医薬 分子生物学（改訂第３版），２０１４年０３月３０日，ｐ．２１３－２１５

Also Published As

Publication number Publication date
CA3057289A1 (en) 2018-09-27
WO2018175581A8 (en) 2018-11-01
JP2023056032A (ja) 2023-04-18
AU2018239433A1 (en) 2019-10-10
EP3599842A4 (en) 2020-12-30
JP2020515248A (ja) 2020-05-28
CN110891417B (zh) 2023-05-23
AU2018239433B2 (en) 2024-02-01
EP3599842B1 (en) 2024-08-07
WO2018175581A1 (en) 2018-09-27
US11957115B2 (en) 2024-04-16
EP3599842A1 (en) 2020-02-05
US20240315220A1 (en) 2024-09-26
US20200022343A1 (en) 2020-01-23
CN110891417A (zh) 2020-03-17

Similar Documents

Publication Publication Date Title
JP7623785B2 (ja) ヒトＡＰＯＥ４およびマウスＴｒｅｍ２ ｐ．Ｒ４７Ｈを発現する遺伝子改変されたマウス、ならびにその使用の方法
Wu et al. Fibroblast growth factor 13 is a microtubule-stabilizing protein regulating neuronal polarization and migration
US20250228219A1 (en) Genetically modified mouse models of alzheimer’s disease
US9631187B2 (en) Methods and compositions for gene correction
US9161995B2 (en) Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
CN111936628B (zh) 阿尔茨海默病动物模型及其应用
KR102296075B1 (ko) epcam 유전자 변이 제브라피쉬 및 이의 용도
JP7134944B2 (ja) 遺伝子改変免疫不全非ヒト動物における改良されたヒト赤血球生存に関連する方法および組成物
US20220192163A1 (en) Hemophilia b rat model
Knüwer Generation of transgenic mice for the investigation of ceramide metabolism
Young Generation of gene disrupted mice to further elucidate the reproductive mechanisms of male factor fertility
Kardakaris Macrophage and endothelial specific role of p38α [p38-alpha] MAPK in atherosclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230217

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230307

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230308

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250117

R150 Certificate of patent or registration of utility model

Ref document number: 7623785

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150